Since anti-VEGF antibody is known to potentiate tumor immunity via normalization of vascular-immune crosstalk [34], it will be interesting in future studies to see whether bevacizumab promotes intratumor immune cell infiltration and changes the CTNNB1-mutated immune-cold TME to an immune-hot TME favorable to atezolizumab therapy. The gene discussed is VEGFA; the disease is neoplasm.